Click here to get full coverage on Myosin XI-1: A key molecular target for salt-tolerant crops - EurekAlert!

Myosin XI-1: A key molecular target for salt-tolerant crops  EurekAlert!

Myosin XI-1: A key molecular target for salt-tolerant crops - EurekAlert!

Click here to get full coverage on ATXI SEC Filings - Avenue Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan

ATXI SEC Filings - Avenue Therapeutics Inc 10-K, 10-Q, 8-K Forms  Stock Titan

ATXI SEC Filings - Avenue Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Click here to get full coverage on Myosin XI-1: A key molecular target for salt-tolerant crops - Phys.org

Myosin XI-1: A key molecular target for salt-tolerant crops  Phys.org

Myosin XI-1: A key molecular target for salt-tolerant crops - Phys.org

Click here to get full coverage on Avenue (OTC: ATXI): Axsome to acquire Baergic; up to $82M milestones, royalties - Stock Titan

Avenue (OTC: ATXI): Axsome to acquire Baergic; up to $82M milestones, royalties  Stock Titan

Avenue (OTC: ATXI): Axsome to acquire Baergic; up to $82M milestones, royalties - Stock Titan

Click here to get full coverage on Will Avenue Therapeutics Stock Bounce Back? - StocksToTrade

Will Avenue Therapeutics Stock Bounce Back?  StocksToTrade

Will Avenue Therapeutics Stock Bounce Back? - StocksToTrade

Click here to get full coverage on Avenue Therapeutics Sells Baergic Bio to Axsome - TipRanks

Avenue Therapeutics Sells Baergic Bio to Axsome  TipRanks

Avenue Therapeutics Sells Baergic Bio to Axsome - TipRanks

Click here to get full coverage on ATXI completes $1.4bn power transmission line project in US - Power Technology

ATXI completes $1.4bn power transmission line project in US  Power Technology

ATXI completes $1.4bn power transmission line project in US - Power Technology

Click here to get full coverage on Avenue Therapeutics faces Nasdaq delisting over equity shortfall - Investing.com

Avenue Therapeutics faces Nasdaq delisting over equity shortfall  Investing.com

Avenue Therapeutics faces Nasdaq delisting over equity shortfall - Investing.com

Click here to get full coverage on ATXI Spring Summer 2024 Collection - dscene magazine

ATXI Spring Summer 2024 Collection  dscene magazine

ATXI Spring Summer 2024 Collection - dscene magazine

Click here to get full coverage on Lightning Alerts: SOUN, ATER, TMPO, and ATXI - RagingBull

Lightning Alerts: SOUN, ATER, TMPO, and ATXI  RagingBull

Lightning Alerts: SOUN, ATER, TMPO, and ATXI - RagingBull

Click here to get full coverage on Avenue Therapeutics (ATXI) - Zacks Investment Research

Avenue Therapeutics (ATXI)  Zacks Investment Research

Avenue Therapeutics (ATXI) - Zacks Investment Research

Click here to get full coverage on MISO Chooses Ameren for 3rd Long-range Tx Project - RTO Insider

MISO Chooses Ameren for 3rd Long-range Tx Project  RTO Insider

MISO Chooses Ameren for 3rd Long-range Tx Project - RTO Insider

Click here to get full coverage on ATXI begins construction on $250M Mark Twain Transmission Project - Transformers Magazine

ATXI begins construction on $250M Mark Twain Transmission Project  Transformers Magazine

ATXI begins construction on $250M Mark Twain Transmission Project - Transformers Magazine

Click here to get full coverage on Ameren Transmission Plans New High-Voltage Line Through Northeast Missouri - NEMOnews Media Group

Ameren Transmission Plans New High-Voltage Line Through Northeast Missouri  NEMOnews Media Group

Ameren Transmission Plans New High-Voltage Line Through Northeast Missouri - NEMOnews Media Group

Click here to get full coverage on Avenue Therapeutics (NASDAQ:ATXI) CEO and President Lucy Lu, M.D., has a Replacement for Medical Opiods - The Wall Street Transcript

Avenue Therapeutics (NASDAQ:ATXI) CEO and President Lucy Lu, M.D., has a Replacement for Medical Opiods  The Wall Street Transcript

Avenue Therapeutics (NASDAQ:ATXI) CEO and President Lucy Lu, M.D., has a Replacement for Medical Opiods - The Wall Street Transcript

Click here to get full coverage on ATXI: No Pain? We See a Gain; Developing Tramadol - Zacks Small Cap Research

ATXI: No Pain? We See a Gain; Developing Tramadol  Zacks Small Cap Research

ATXI: No Pain? We See a Gain; Developing Tramadol - Zacks Small Cap Research

Click here to get full coverage on Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - GlobeNewswire

Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights  GlobeNewswire

Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - GlobeNewswire

Click here to get full coverage on Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease) - Stock Titan

Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)  Stock Titan

Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease) - Stock Titan

Click here to get full coverage on Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday  InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday - InvestorPlace

Click here to get full coverage on Ameren Completes, Energizes Illinois Rivers Transmission Project - North American Windpower

Ameren Completes, Energizes Illinois Rivers Transmission Project  North American Windpower

Ameren Completes, Energizes Illinois Rivers Transmission Project - North American Windpower

Click here to get full coverage on Tokina atx-i 100mm f/2.8 FF Macro Lens Announced - Newsshooter

Tokina atx-i 100mm f/2.8 FF Macro Lens Announced  Newsshooter

Tokina atx-i 100mm f/2.8 FF Macro Lens Announced - Newsshooter

Click here to get full coverage on Ameren to build 95-mile transmission line through 5 northeast counties - The Missouri Times

Ameren to build 95-mile transmission line through 5 northeast counties  The Missouri Times

Ameren to build 95-mile transmission line through 5 northeast counties - The Missouri Times

Click here to get full coverage on Avenue Therapeutics Completes the Acquisition of Baergic Bio - citybiz

Avenue Therapeutics Completes the Acquisition of Baergic Bio  citybiz

Avenue Therapeutics Completes the Acquisition of Baergic Bio - citybiz

Click here to get full coverage on BACKSTAGE AT ATXI SS25 « EGOITZA » IN BIARRITZ - CRASH Magazine

BACKSTAGE AT ATXI SS25 « EGOITZA » IN BIARRITZ  CRASH Magazine

ATXI

Price Chart

Key Statistics

Technicals

About ATXI

Latest News

Myosin XI-1: A key molecular target for salt-tolerant crops - EurekAlert!

ATXI SEC Filings - Avenue Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Myosin XI-1: A key molecular target for salt-tolerant crops - Phys.org

Advanced Charts

Top Gainers

Top Losers